Justmet Safe 2 Tablet ER is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (2 mg), Metformin (500 mg), and Voglibose (0.2 mg), each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose concentrations. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, facilitating improved glucose uptake in muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, attenuating postprandial hyperglycemia. The extended-release (ER) formulation ensures sustained drug release, promoting better adherence and stable plasma drug levels. Justmet Safe 2 Tablet ER is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy. It should be used with caution in patients with renal or hepatic impairment and contraindicated in those with known hypersensitivity to any component, diabetic ketoacidosis, or severe infections. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy. This combination therapy offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological defects.